Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States

• DOI: 10.1007/s40121-023-00798-x
• Publication Date: 2023-04-20T12:22:16Z
• Authors: Johnna Perdrizet; Emily K. Horn; Kyla Hayford; Lindsay Grant; Rachid Barry; Liping Huang; Cheryl McDade; Michele Wilson
• Keywords: Pneumococcal Conjugate Vaccine

This study estimates the annual population-level impact of 13-valent pneumococcal conjugate vaccine (PCV13) infant national immunization programs (NIPs) on vaccine-type and non-vaccine type invasive disease (IPD) incidence across all ages using surveillance data.We identified countries (Australia, Canada, England Wales, Israel, US) with IPD active data that introduced seven-valent PCV (PCV7) followed by PCV13, which also reported serotype- age group-specific incidence. We extracted serotype groupings [PCV13 minus PCV7 (PCV13-7) serotypes; PCV13-7 serotypes excluding 3; non-PCV13 20-valent (PCV20) PCV13 (PCV20-13) serotypes] groups (< 2 years, 2-4 5-17 18-34 35-49 50-64 ≥ 65 years). For each country, we calculated relative change in (percent change), corresponding rate ratio (IRR), for 7 years post introduction compared to year prior program initiation.PCV13-7 consistently decreased over time following countries, reaching an approximate steady state after 3-4 < 5 roughly 60-90% decrease (IRRs = 0.1-0.4) 4-5 approximately 60-80% 0.2-0.4). Incidence declines were more substantial grouping when 3. Non-PCV13 was variable country group, ranging from virtually no replacement period US increases other 10 204% 1.10-3.04) children 41% 123% 1.41-2.23) years.Countries longstanding NIPs have observed direct indirect benefits, are demonstrated this reduction groups. Over time, emerged response PCV13-unique serotypes. Higher-valent PCVs needed address emerging burden as well vaccination both pediatric adult populations against most prevalent circulating